Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

Core Viewpoint - Dyne Therapeutics, Inc. has announced an upsized underwritten public offering of 18,980,478 shares at a price of $18.44 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering consists of 18,980,478 shares of common stock priced at $18.44 each, with expected gross proceeds of $350 million [1]. - The offering is set to close on or about December 11, 2025, pending customary closing conditions [1]. - Dyne has granted underwriters a 30-day option to purchase an additional 2,847,071 shares at the public offering price [1]. Group 2: Underwriters - Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering [2]. Group 3: Regulatory Information - The offering is made under a shelf registration statement filed with the SEC on March 5, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Group 4: Company Overview - Dyne Therapeutics focuses on improving the functionality of individuals with genetically driven neuromuscular diseases, developing therapeutics targeting muscle and the central nervous system [5]. - The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), along with preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5].